Evidence map›Paper›PMID 38496503›Full record

ArticlebioRxiv : the preprint server for biology2024

Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing.

Minjing Wang, Joshua B Krueger, Alexandria K Gilkey, Erin M Stelljes, Mitchell G Kluesner, Emily J Pomeroy, Joseph G Skeate, Nicholas J Slipek, Walker S Lahr, Patricia N Claudio Vázquez and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Minjing WangDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-4725-8351
Joshua B KruegerDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0009-0002-7658-149X
Alexandria K GilkeyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Erin M StelljesDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Mitchell G KluesnerDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-5828-9204
Emily J PomeroyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-7690-3570
Joseph G SkeateDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-1765-5949
Nicholas J SlipekDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-2664-6507
Walker S LahrDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-3288-3843
Patricia N Claudio VázquezDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-2754-4895
Yueting ZhaoDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0009-0002-6122-8108
Ella J EatonDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-9861-0437
Kanut LaoharaweeDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-8216-2131
Beau R WebberDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-3950-8747
Branden S MoriarityDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-3031-3767
University of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-VirotherapyU54CA232561 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI CRIPE, TIMOTHY P · 2019 to 2023
$12.1M
Project 3P01CA254849 · NCI · UNIVERSITY OF MINNESOTA · PI LARGAESPADA, DAVID ANDREW, MASOPUST, DAVID · 2021 to 2025
$9.4M
TECH CoreU54CA268069 · NCI · UNIVERSITY OF MINNESOTA · PI Kevin William Eliceiri, Paolo Provenzano · 2022 to 2026
$8.2M
SCGE Disease Models Studies Supplement: Evaluation of prime editing for the amelioration of alpha-1-antitrypsin deficiency in murine and porcine models.U24OD026641 · OD · RECOMBINETICS, INC. · PI CARLSON, DANIEL FRED · 2018 to 2022
$4.1M
Activated NK CAR Cells to Cure HIVR01AI161017 · NIAID · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S, SKINNER, PAMELA J · 2021 to 2025
$3.8M
Engineered B Cells as a Universal Platform for the Treatment of EnzymopathiesR01AI146009 · NIAID · UNIVERSITY OF MINNESOTA · PI MORIARITY, BRANDEN S · 2020 to 2024
$1.9M
Multiplex Engineered Human Lymphocytes for Therapeutic Protein DeliveryR21AI163731 · NIAID · UNIVERSITY OF MINNESOTA · PI WEBBER, BEAU RICHARD · 2021 to 2022
$426k
Determining the cell of origin in Ewing sarcoma through genomic analysisR21CA237789 · NCI · UNIVERSITY OF MINNESOTA · PI SPECTOR, LOGAN G., WEBBER, BEAU RICHARD · 2020 to 2021
$396k
NCI NIH HHS P01 CA254849NCI NIH HHS P30 CA077598NCI NIH HHS P50 CA136393NCI NIH HHS R21 CA237789NCI NIH HHS U54 CA232561NCI NIH HHS U54 CA268069NIAID NIH HHS R01 AI146009NIAID NIH HHS R01 AI161017NIAID NIH HHS R21 AI163731NIH HHS U24 OD026641
6 · The paper itself

Abstract

Natural killer (NK) cells' unique ability to kill transformed cells expressing stress ligands or lacking major histocompatibility complexes (MHC) has prompted their development for immunotherapy. However, NK cells have demonstrated only moderate responses against cancer in clinical trials and likely require advanced genome engineering to reach their full potential as a cancer therapeutic. Multiplex genome editing with CRISPR/Cas9 base editors (BE) has been used to enhance T cell function and has already entered clinical trials but has not been reported in human NK cells. Here, we report the first application of BE in primary NK cells to achieve both loss-of-function and gain-of-function mutations. We observed highly efficient single and multiplex base editing, resulting in significantly enhanced NK cell function. Next, we combined multiplex BE with non-viral

Identifiers

PMID38496503
PMCPMC10942345
OpenAlexW4392624646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.